Page 2 - Nasdaq Immx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Immx Today - Breaking & Trending Today

Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Increases By 71.7%

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 172,200 shares, an increase of 71.7% from the September 30th total of 100,300 shares. Approximately 2.3% of the shares of the company are sold short. Based […] ....

South Australia , United States , Roth Mkm , Melissa Jane Buchan , Securities Exchange Commission , Blackrock Inc , Susquehanna International Group , Immix Biopharma Inc , Renaissance Technologies , Topco Ltd , Virtu Financial , Immix Biopharma , Get Free Report , Director Melissa Jane Buchan , Exchange Commission , International Group , Biopharma Trading Down , Immix Biopharma Daily , Nasdaq Immx ,

Contrasting Immix Biopharma (IMMX) and Its Peers

Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 888 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Immix Biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk […] ....

United States , Los Angeles , Beigene Ltd , Immix Biopharma Inc , Immix Biopharma , Get Free Report , Given Immix Biopharma , Immix Biopharma Daily , Nasdaq Immx , Stock Comparison , Stock Analysis ,

Immix Biopharma (IMMX) versus The Competition Critical Comparison

Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 975 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Immix Biopharma to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership. Volatility & Risk Immix Biopharma […] ....

United States , Los Angeles , Beigene Ltd , Immix Biopharma Inc , Immix Biopharma , Get Free Report , Given Immix Biopharma , Immix Biopharma Daily , Nasdaq Immx , Stock Comparison , Stock Analysis ,

Melissa Jane Buchan Buys 20,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) Director Melissa Jane Buchan purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was acquired at an average cost of $2.46 per share, with a total value of $49,200.00. Following the purchase, the director now directly owns 20,000 […] ....

United States , Roth Mkm , Melissa Jane Buchan , Murchinson Ltd , Immix Biopharma Company Profile , Koshinski Asset Management Inc , Vanguard Group Inc , Immix Biopharma Inc , Renaissance Technologies , Immix Biopharma , Get Free Report , Director Melissa Jane Buchan , Koshinski Asset Management , Immix Biopharma Daily , Nasdaq Immx , Insider Trading , Nsider Trades ,

Nexcella, Immix Biopharma Subsidiary, to Present at the

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage. ....

United States , Mike Moyer , Los Angeles , Ilya Rachman , Gabriel Morris , Immix Biopharma Inc , Company Conference , Nexcella Inc , Exchange Commission , Chief Executive Officer , Chief Financial Officer , Immix Biopharma , Tissue Specific Therapeutics , Tissue Specific Therapeutic , Orphan Drug Designation , Rare Pediatric Disease Designation , Risk Factor , Annual Report , Nasdaq Immx , Immix Biopharma ,